Bella Neufeld, PhD, on Addressing Pain Points in AAV Gene Therapy Development
The director of research and development at Teknova discussed the company’s recent announcement of a new line of products intended to streamline process development in AAV gene therapy manufacturing.
“...We have essentially developed an entire research and development team of AAV experts to try to understand where the pain points are. Many people are surprised to hear that a company that's been around for 25 years making agar plates and buffers have put the infrastructure in to have an end-to-end AAV platform in-house, but that's exactly what we've done. The reason that we've done that is because we really want to understand this workflow and to be able to develop novel solutions that address the pain points in that workflow.”
Teknova recently announced a new line of products intended to streamline manufacturing process development for adeno-associated virus (AAV) vector-based gene therapies. The first product in this line,
In an interview with CGTLive™, Bella Neufeld, PhD, the director of research and development at Teknova, discussed the company’s future plans for the product line and how they could potentially impact gene therapy development. She highlighted the fact that the company has installed an end-to-end AAV platform in-house in order to better examine AAV gene therapy manufacturing workflow and identify additional areas of interest for improvement. Neufeld also discussed the AAV-Tek AEX Buffer Screening Kit in more detail and emphasized that Teknova’s consultation services for the buffer selection process will be a key part of the product’s impact.
REFERENCE
Teknova launches proprietary AAV-Tek™ solutions gene therapy product line to accelerate the development of AAV therapies. News release. Alpha Teknova, Inc. May 2, 2023. Accessed June 26, 2023. https://ir.teknova.com/news-releases/news-release-details/teknova-launches-proprietary-aav-tektm-solutions-gene-therapy
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025